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Malignant cancer is a devastating disease often associated with a poor clinical
prognosis. For decades, modern drug discoveries have attempted to identify potential
modulators that can impede tumor growth. Cancer stem cells however are more resistant
to therapeutic intervention, which often leads to treatment failure and subsequent
disease recurrence. Here in this study, we have developed a specific multi-target drug
delivery nanoparticle system against breast cancer stem cells (BCSCs). Therapeutic
agents curcumin and salinomycin have complementary functions of limiting therapeutic
resistance and eliciting cellular death, respectively. By conjugation of CD44 cell-surface
glycoprotein with poly(lactic-co-glycolic acid) (PLGA) nanoparticles that are loaded with
curcumin and salinomycin, we investigated the cellular uptake of BCSCs, drug release,
and therapeutic efficacy against BCSCs. We determined CD44-targeting co-delivery
nanoparticles are highly efficacious against BCSCs by inducing G1 cell cycle arrest and
limiting epithelial–mesenchymal transition. This curcumin and salinomycin co-delivery
system can be an efficient treatment approach to target malignant cancer without the
repercussion of disease recurrence.
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INTRODUCTION
Resistance to chemotherapy is the major cause of cancer relapse and mortality. Early indications
of intrinsic resistance emphasized on the presence of cancer stem cells (CSCs), which are highly
mesenchymal in nature and have the ability to self-renew, differentiate, and promote tumorigenesis.
They play an important role in chemotherapy and radiotherapy resistance via enhanced anti-
apoptotic, DNA repair, and reactive oxygen species (ROS)-protective mechanisms, often leading
to tumor recurrence including metastasis. There is now overwhelming clinical evidence to support
enriched CSCs as the dominant population in reviving tumor growth despite initial aggressive
chemotherapeutic intervention. Therefore, effective elimination of CSCs is essential to impede
tumor relapse and drug resistance to improve patients’ survival. However, current treatments
may harm the normal stem cell pool and result in severe side effects. Therefore, therapeutics to
specifically remove CSCs remain a major challenge for anti-cancer treatment.
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Salinomycin is a polyether ionophore antibiotic with efficacy
as an anti-cancer drug (Naujokat and Steinhart, 2012). Pre-
clinical data indicates salinomycin has the potential to reduce
tumorigenicity by targeting CSCs and has been effective in several
cancer types (Gupta et al., 2009; Lu et al., 2011; Ketola et al., 2012;
Lim et al., 2020). The anti-cancer mechanism of salinomycin is
associated with dysregulation of metal ions (Paulus et al., 1998),
activation of autophagy-mediated cell death, and inhibition of
stem cell maintenance (Lu et al., 2011; Yue et al., 2013; Mai
et al., 2017). A recent study found that salinomycin and its
derivative, ironomycin, exhibited a potent and selective activity
against breast cancer stem cells (BCSCs) by accumulating and
sequestering iron to induce ferroptosis, which is a recently
described form of iron-dependent cell death marked by the
oxidative modification of phospholipid membranes (Mai et al.,
2017). However, it is challenging to efficiently deliver salinomycin
(Sal) to tumor sites due to its hydrophobicity, unfavorable
pharmacokinetic profile, and cytotoxicity during systemic drug
administration (Naujokat and Steinhart, 2012). Curcumin (Cur)
is a bioactive ingredient derived from the root of Curcuma
longa L, which have been widely used in the prevention and
treatment of a number of diseases, including cancer (Sharma
et al., 2005; Zhou et al., 2011; Shanmugam et al., 2015; Gao
et al., 2017; Motevalli et al., 2019). Curcumin is a potent tumor
suppressor as it can inhibit tumor growth at cellular and in vivo
level. Although the mechanism is not fully understood, studies
have shown that curcumin can lead to inhibition of cancer cell
invasion (Baek et al., 2003; Shao et al., 2017), cell cycle arrest, and
induction of autophagic cell death. More recently, researchers
have investigated the anti-metastasis potentials of curcumin
(Basnet and Skalko-Basnet, 2011; Norris et al., 2013; Teiten et al.,
2014; Kotcherlakota et al., 2016) and found it can inhibit CSCs’
viability and their stemness via ROS and the signal transducer
and activator of transcription 3 (STAT3) signaling pathway
(Buhrmann et al., 2020). However, its therapeutic potential is
limited due to its rapid metabolism and poor solubility and
absorption (Tsai et al., 2011).
Nanomedicines provide new strategies in cancer targeting and
treatment due to high drug loading capability, cancer-targeting
ability, and even the potential to overcome the efflux pump-
mediated drug resistance by delivering a high concentration
of intracellular drugs (Cho et al., 2008). Our previous studies
showed that conjugation of salinomycin with gold nanoparticles
can efficiently induce ferroptotic cell death of BCSCs by
increasing the generation of ROS, mitochondrial dysfunction,
and lipid oxidation with higher iron accumulation and GPX-
4 inactivation (Zhao et al., 2019). Here, the combination of
salinomycin and curcumin was used to achieve synergetic effect
in treating BCSCs. Salinomycin and curcumin were loaded onto
poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles via
double emulsion method to form nanoparticles (Avgoustakis
et al., 2002; Alam et al., 2017). Additionally, hyaluronic acid
(HA) was also conjugated to nanoparticles as targeting moiety
due to its specific interaction with the CD44 receptor, which
is a cell surface glycoprotein and commonly overexpressed on
BCSCs (Zöller, 2011; Ganesh et al., 2013; Sanfilippo et al., 2020).
The CD44-targeting nanoparticles loaded with salinomycin
and curcumin showed improved therapeutic efficiency against




Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine
serum (FBS), penicillin–streptomycin, propidium iodide, Triton
X-100, PageRuler Prestained Protein Ladder, and nitrocellulose
membrane were purchased from Thermo Fisher. Curcumin,
salinomycin, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC), and N-hydroxysuccinimide (NHS) were
bought from Sigma-Aldrich and used directly without any
purification. Mouse anti-vimentin, mouse anti-E-cadherin, and
rabbit anti-β-actin primary antibodies purchased from Abcam.
Odyssey blocking buffer, IRDye R© 800CW goat anti-mouse
secondary antibody, and IRDye R© 680RD goat anti-rabbit
secondary antibody were purchased from LI-COR.
Nanoparticle Synthesis and Surface
Functionalization
NH2-PEG-NH2 (MW: 3.4 k), PLGA (MW: 10 k), and
PLGA-PEG-NH2 (MW: 18.6 k) co-polymer were bought
from Meiluo Tech Company. Curcumin and salinomycin
were loaded into the PLGA-PEG-NH2 copolymer via the well-
established double emulsion method (Avgoustakis et al., 2002).
Briefly, curcumin (1 mg/ml) and salinomycin (molar ratio of
Cur and Sal = 1:1) were dissolved in organic phase containing
co-polymer (1.75%, w/v), and the mixture was mixed using an
ultrasonic homogenizer (LABSONIC M, Sartorius, Germany).
The primary particles were added into a PVA solution (10ml,
2%, w/v), and the mixture was sonicated again. The free drugs
were then removed by centrifugation at 20,000 rpm for 15min
and washed with water. The formed nanoparticles were labeled
as PEG-PLGA-Cur-Sal.
After drug loading, targeting moiety HA was conjugated onto
the polymeric nanoparticles via EDC coupling. Briefly, desalted
HA (1 equivalent), EDC (3 equivalents), and NHS (3 equivalents)
were dissolved in 2-(N-morpholino)ethanesulfonic acid (MES)
buffer and stir in ice bath to activate carboxylic group for half an
hour. PEG-PLGA-Cur-Sal was then added and the mixture was
stirred for another 4 h at room temperature to form nanoparticles
named HA-PEG-PLGA-Cur-Sal. They were purified by using
centrifugation at 20,000 rpm for 15 min.
Characterization of the Nanoparticles
1H NMR spectra were acquired on a Bruker AVANCE 400 MHz
spectrometer. A gel permeation chromatography—multi-angle
laser light scattering (GPC-MALLS) system consisting of a 1,515
isocratic pump (Waters), Styragel HT 6E and Styragel HT 3
columns (Waters), 2,414 differential refractive index detector
(Waters), and a DAWN HELEOS laser light scattering detector
(Wyatt) with THF as an eluent at a flow rate of 1 ml/min was
used to measure the molecular weight and dispersity of the
polymers. After drug loading, the size of the nanoparticles was
measured via dynamic light scattering (DLS) to measure the
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hydrodynamic diameter using a Malvern Zetasizer, and a Philips
CM100 transmission electron microscope (TEM) was also used
to observe their morphology.
Cancer Stem Cell Culture
MCF-7 cells were bought from ATCC (USA) and cultured
in DMEM medium containing 10% (v/v) FBS and 1% (v/v)
penicillin–streptomycin. They were kept in a humidified 37◦C
incubator with 5% CO2. After serum-free treatment, BCSC sub-
populations in the MCF-7 cells were isolated using MagCellect
Human BCSC isolation kit (R&D Systems) according to
protocols from the manufacturer. In brief, MCF-7 cells (1 × 107
cells/ml) were prepared in buffer and mixed with anti-human
CD24 biotinylated antibody and then Streptavidin Ferrofluid
for selection of CD24low cells. Those cells were subsequently
incubated with a biotinylated anti-human CD44 antibody and
Streptavidin Ferrofluid for selection of CD44high cells. After
washing, magnetically tagged CD24low/CD44high BCSCs were
isolated through the magnet. The cells were directly treated with
drug-loaded nanoparticles and control samples after isolation.
Drug Loading Efficiency and Drug Release
Study
Salinomycin loading efficiency was analyzed by using a UV-Vis-
NIR spectrophotometer following a published method (Wang
et al., 2014). The drug concentration of curcumin was calculated
using the linear portion of the calibration curve obtained by the
UV spectrophotometer at 427 nm for serial drug concentrations.
Cellular Uptake Assay With Flow
Cytometry
Flow cytometry was used to quantify cellular interaction
following incubation of the cells with each treatment group.
BCSCs were seeded in six-well culture plates (2× 105 cells/well).
Fluorescent dye Cy5.5 was encapsulated in the nanoparticles
(NPs) to image cellular uptake. After pre-incubation for 24 h,
cells were treated with HA-PEG-PLGA NPs and PEG-PLGA
NPs, respectively. After 6 h, the cells were washed with PBS
twice and cells of each well were collected and imaged using a
FACSCanto A flow cytometer (BD Bioscience, USA). Fluorescent
dye coumarin-6 was encapsulated in the NPs, and cellular uptake
wasmonitored using a Leica TCS SP8 CARS confocal microscope
(Leica, Germany) after 4-h incubation of untargeted PEG-PLGA
NPs and targeted HA-PEG-PLGA NPs.
Proliferation Assay
Cells were seeded at 800 cells per well in 96-well plates and
cultured until they reached ∼10% confluence. Cells were then
treated overnight with various concentrations of drug-loaded
nanoparticles or controls. Cell proliferation was monitored using
the Incucyte Zoom (Essen, MI, USA). Images were taken at
regular time intervals over 6 days, and cell growth curves were
plotted with the Incucyte Zoom software.
Cell Cycle G1/S Assessment Using Flow
Cytometry
Cells were seeded onto six-well plates and cultured overnight
until they reached 80% confluence. After a subsequent 24-h
treatment with drug-loaded nanoparticles or the relevant control,
the cells were treated with 300 µl of 1 mg/ml propidium iodide,
0.1% (v/v) Triton X-100, and 0.8% (v/v) RNAse A solution
for 30min at room temperature. Cells were washed with PBS
and harvested for cell cycle measurements while protected from
light. Single cells were identified by measurement of forward
and side scatter. Then, doublets were removed using pulse
processing. Measurements took place using a B670LP-A filter on
a FACSCanto A flow cytometer.
Wound Scratch Assays
Cell migration was assessed using an established wound scratch
assay (Fan et al., 2011). Cells were seeded at 64,000 cells per well
in 96-well plates and incubated until they reached more than
80% confluence. The plates were placed in an Incucyte wound
maker (Essen, MI, USA) to ensure consistency in the wounds
made on the cell monolayers in each well. The medium and cell
debris were then removed and replaced with 200 µl of fresh
medium containing drug-loaded nanoparticles or controls. The
plates were placed in the Incucyte Zoom (Essen, MI, USA), and
the wound width was monitored over 24 h for later analysis using
Incucyte Zoom software.
Cell Attachment
Cells were seeded onto six-well plates and left to attach overnight
until over 80% confluence and then treated with drug-loaded
nanoparticles or controls for 24 h. The cells were washed with
PBS and then detached using versene. They were then seeded 5
× 104 cells per well onto gelatin-precoated 96-well plates for 2 h.
After washing with PBS and fixation using 4% PFA for 15min,
the cells were imaged using the Incucyte Zoom (Essen, MI, USA)
and the number of cells attached was quantified using Incucyte
Zoom software.
Western Blotting
The expression of EMTmarkers was assessed by western blotting.
Cells were seeded onto six-well plates and cultured overnight
until they reached over 80% confluence. They were then treated
with drug-loaded nanoparticles or controls for 24 h, washed with
PBS, and harvested with versene. Ice-cold lysis buffer was added
to each cell pellet for 15min, and protein supernatants were
obtained after spinning at 16,000G for 15min at 4◦C. The total
protein concentration in each extract was measured using the
bicinchoninic acid protein assay.
Protein samples were diluted using Milli-Q water to give a
concentration of 50 µg protein/20 µl. Loading buffer (5 µl)
was added to each sample, and samples were heated at 75◦C
for 10min. Samples were loaded into wells of 15% acrylamide
gels with a protein ladder and run at 100V. The proteins
were subsequently transferred onto nitrocellulose membranes
at 100V for 1 h, then blocked with 5ml of blocking buffer at
4◦C overnight. Blots were treated with a mouse anti-vimentin
monoclonal antibody (1:1,000) or a mouse anti-E-cadherin
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monoclonal antibody (1:1,000) in blocking buffer for 1 h at room
temperature on a shaker, while a rabbit anti-β-actin monoclonal
antibody was used as a loading control (1:1,000). After washing
with 1X TBST four times every 15min for 1 h, the blots were
incubated with goat anti-mouse polyclonal secondary antibodies
(1:5,000) in the dark for 1 h. After washing for four times and
drying, the membranes were scanned with the Odyssey CLx (LI-
COR, NE, USA) imaging system and data were analyzed with
Image Studio software.
Statistical Analysis
Multiple group comparisons were carried out using T-test, using
GraphPad Prism version 7. This enabled significance against
DMSO controls to be calculated. All results are shown as mean
± SEM of at least three replicates.
RESULT AND DISCUSSION
Nanoparticle Preparation and Drug
Loading
PLGA-PEG-NH2 co-polymer was validated via
1H NMR
spectrum (Supplementary Figure 2). PLGA-PEG-NH2 co-
polymer showed both the characteristic peak of PLGA (methyl
group: 1.44–1.83 ppm and multiple peaks: 5.17–5.40 and 4.66–
4.89 ppm) and the typical peak of PEG in which the methane
proton is around 3.62 ppm (CH2-CH2-O) and validated
the successful conjugation of PLGA-PEG-NH2. PLGA-PEG
nanoparticles loaded with salinomycin and curcumin were
prepared using the well-established double emulsion solvent
evaporation method (Avgoustakis et al., 2002; You et al., 2018).
HA was conjugated onto nanoparticles via EDC coupling
and confirmed by hexadecyltrimethylammonium bromide
(CTAB) turbidimetric method (Chen and Wang, 2009; Song
et al., 2009). The hydrodynamic size of the nanoparticles
increased from 120.1 ± 5.5 to 153.4 ± 4.6 nm after conjugation
FIGURE 1 | In vitro release profiles of Cur and Sal from
HA-PEG-PLGA-Cur-Sal nanoparticles in sodium phosphate buffer at pH 5.0
and pH 7.4 at 37◦C, respectively. Error bars show mean ± standard deviation
from experiments performed in triplicate.
with HA, which was measured by dynamic light scattering
(Table 1). Nanoparticle morphology was confirmed by TEM
(Supplementary Figure 1). The surface charge also exhibited
a negative zeta potential value after HA conjugation because
of the negative carboxylic moiety of HA, which confirmed
the conjugation of HA onto the particles. Approximately
70% of salinomycin and 82% of curcumin were loaded in
polymeric nanoparticles, characterized by measuring UV-
Vis spectra. Free salinomycin and curcumin molecules were
separated from the solution and subsequently removed
by centrifugation.
Drug Release Study
The kinetics of the drug release was evaluated over time upon
their in vitro incubation in PBS buffer at 37◦C, and the results
are summarized in Figure 1. The higher hydrophilic moiety of
PEG amount in co-polymer contributed to greater drug release.
During the initial hours, there was a rapid release that led to a
higher loading of salinomycin and curcumin in the vicinity of
the surface and faster drug diffusion (Panagi et al., 2001; Wang
et al., 2013). After 12 h, levels of salinomycin and curcumin
were observed as a sustained curve, possibly due to the slow
release of drugs within the polymeric matrix. Post-24 h,∼88% of
salinomycin and 90% of curcumin were released from polymeric
nanoparticles when pH was 7.4. When pH was reduced to 5.0,
∼96% of salinomycin and 94% of curcumin were released. This
data suggests both salinomycin and curcumin can be released
from the polymeric nanoparticles under a similar condition and
is expected when coming in contact with tumor tissues.
In vitro CD44-Mediated Cellular Uptake
Flow cytometry analysis was used to determine the
internalization of HA-PEG-PLGA NPs by cancer cells and
if this correlation is associated with the over-expression of CD44
FIGURE 2 | Cell uptake of HA-PEG-PLGA NPs and PEG-PLGA NPs by flow
cytometry. The BCSCs were incubated with different formulations for 6 h. Data
are mean ± SD (n = 3) (***p < 0.001, ****p < 0.0001).
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receptor. BCSCs treated with HA-PEG-PLGA NPs showed
a higher fluorescence intensity than BCSCs incubated with
PEG-PLGA NPs after 6 h. This is due to a HA receptor that leads
to cellular internalization via HA receptor-mediated endocytosis.
As shown in Figure 2, the cellular association of HA-PEG-PLGA
NPs was approximately three times greater than non-specific
PEG-PLGA NPs at 37◦C. This suggests HA-PEG-PLGA NPs
could enter into the cell membrane and efficiently target cells by
binding with CD44 that is overexpressed in BCSCs. HA targeting
ability was also confirmed by confocal fluorescence micrograph
of MCF-7 cells after 4-h incubation of untargeted PEG-PLGA
NPs and targeted HA-PEG-PLGA NPs at the same concentration
of coumarin-6. Significant fluorescence signal of coumarin-6 was
observed in HA-PEG-PLGA NPs (Supplementary Figure 3).
In vitro Cell Proliferation and Viability
The in vitro cytotoxicity analysis was grouped as follows:
HA-PEG-PLGA-Cur-Sal, PEG-PLGA-Cur-Sal, PEG-PLGA-Cur,
PEG-PLGA-Sal, PEG-PLGA, Cur, and Sal. These compounds
were evaluated against BCSCs by using cell proliferation
assay with an incubation period of 144 h. The cytotoxicity
data of BCSCs summarized in Figure 3A show the different
formulations using a series of eight different concentrations
of Sal and each group received the same corresponding Sal
concentration. Cur was kept at a constant concentration.
From Figure 3A, HA-PEG-PLGA-Cur-Sal, which has a specific
affinity with over-expressed CD44 receptor, showed the greatest
cytotoxicity as compared to the remaining formulations at
the same drug concentration. Additionally, PEG-PLGA-Cur-
Sal showed increased cytotoxicity compared to formulations
containing either Cur or Sal. ED50 values were derived as
described by Tallarida (2011), and synergism was observed
in both HA-PEG-PLGA-Cur-Sal and PEG-PLGA-Cur-Sal that
exhibited a super-additive effect.
Cell Cycle Arrest Study
Chemotherapeutic drugs are highly toxic to the progression of
cell cycle and thus can promote cellular death. To determine
whether the drugs and their formulations cause cell cycle arrest,
we investigate cell cycle progression by flow cytometry. The
G1 phase of cell cycle is the initial cell cycle phase in which
cells progress for subsequent duplication of itself. As shown
in Figure 3B, both HA-PEG-PLGA-Cur-Sal and PEG-PLGA-
Cur-Sal can significantly prolong the G1/S phase of the cell
cycle, while HA-PEG-PLGA-Cur-Sal promoted G1/S arrest to a
greater extent than the PEG-PLGA-Cur-Sal group. This suggests
that HA-PEG-PLGA-Cur-Sal is the most effective in preventing
BCSCs from subsequent progression into S-phase in which the
genome duplication occurs. This indicates that co-delivery of
salinomycin and curcumin causes extensive G1/S arrest, leading
to the subsequent activation of apoptosis.
Cell Migration and EMT
BCSCs play a pivotal role in migration, which is essential
for the pathogenesis of cancer during invasion and metastasis.
Conversely, lack of cellular migration can lead to a failure in
regenerative therapies. To validate cell migration in vitro, we
adopted wound-healing assay which is widely used as a model
to determine cell migration in vivo. As shown in Figures 4A,B,
BCSCs treated with HA-PEG-PLGA-Cur-Sal showed significant
reduction of cell migration in both wound length and rate
of wound closure when compared to other treated groups.
FIGURE 3 | (A) Cell proliferation study of HA-PEG-PLGA-Cur-Sal, PEG-PLGA-Cur-Sal, PEG-PLGA-Cur, PEG-PLGA-Sal, PEG-PLGA, Cur, and Sal against CSCs. (B)
Cell cycle arrest study of HA-PEG-PLGA-Cur-Sal, PEG-PLGA-Cur-Sal, PEG-PLGA-Cur, PEG-PLGA-Sal, PEG-PLGA, Cur, and Sal against CSCs. Values are means ±
standard deviations (n = 5, S.D.) (*p < 0.05, **p < 0.01).
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FIGURE 4 | Cell migration behavior after treatment of PEG-PLGA-Cur, PEG-PLGA-Sal, PEG-PLGA, Cur, and Sal against CSCs using wound healing assay: (A)
wound closure length, (B) wound closure rate, and (C) percentage of confluency of wound healing assay. (D) Expression of epithelial–mesenchymal transition markers
of HA-PEG-PLGA-Cur-Sal, PEG-PLGA-Cur-Sal, free Cur + free Sal, Cur, and Sal. Values are means ± standard deviations (n = 5, S.D.) (**p < 0.01, ****p < 0.0001).
The lack of migration has a direct impact on cancer cell
invasion and tumor metastasis. In Figure 4C, data indicated
BCSCs that received HA-PEG-PLGA-Cur-Sal treatment had the
lowest cellular confluency during cell attachment assay due to
its reduced adhesion ability of BCSCs. Figure 4D shows that
the immunoblotting of vimentin (mesenchymal marker) and
E-cadherin (epithelial maker) confirmed HA-PEG-PLGA-Cur-
Sal could reverse the properties of EMT, thereby limiting BCSCs
to migrate.
CONCLUSION
In summary, PLGA nanoparticle delivery system co-loaded
with anticancer drug Sal and Cur was successfully synthesized
and functionalized with HA as a targeting moiety. BCSCs
showed higher sensitivity to this formulation with a combination
of Sal and Cur by not only efficiently inducing cell death









PEG-PLGA-Cur-Sal 120.1 ± 5.5 −3.1 ± 0.2 70 82
HA-PEG-PLGA-Cur-Sal 153.4 ± 4.6 −32.6 ± 2.5 – –
aDetermined by DLS.
bDetermined by UV-Vis spectroscopy.
but also inhibiting cell migration and attachment. Our study
revealed HA-PEG-PLGA-Cur-Sal could impede G1 phase cell
cycle progression, leading to cell cycle arrest and subsequent
induction of induced apoptosis of BCSCs. Collectively, our
findings suggest that the combination HA-PEG-PLGA-Cur-
Sal is an efficient therapeutic strategy against BCSCs and
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has the potential of treating tumor metastasis and improve
patient outcome.
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